ArticleLasers in medical science2025
A high-power near-infrared photobiomodulation device: design, fabrication, and primary impact on treatment-resistant depression.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a prevalent psychiatric disorder, affecting a significant portion of the population. However, approximately 30% of patients do not respond adequately to conventional treatments and develop treatment-resistant depression. Despite notable advancements in psychiatry, effectively treating individuals with treatment-resistant depression remains a significant challenge. Photobiomodulation represents an emerging therapeutic approach for depression, utilizing an enhanced near-infrared therapy device. The objective of this study was to evaluate the primary effects of the usage of high-power enhanced near-infrared therapy device on patients suffering from treatment-resistant depression. In this open-label, four-week study, seven right-handed patients categorized as treatment-resistant depression were recruited. Each participant received a daily 2 min intervention (continuous wave; 850 nm peak wavelength; average irradiance of 127 mW/cm²; average fluence per pulse of 6.35 mJ/cm²; total energy delivered per session of 0.3 kJ; output optical power set to 5000 milliwatts; electromagnetic waves set to 10 Hz). Depression severity was assessed using the Hamilton Depression Rating Scale (HAM-D) before and four weeks after the completion of the intervention. During the treatment, each patient underwent eight treatment sessions, each lasting 2 min: first, the device was applied to the left frontal (F3) area, near the left prefrontal cortex, and then, to the right frontal area (F4) on the forehead. Notably, the depression scores showed a significant reduction after four weeks of treatment. The median HAM-D score decreased from 23 before the intervention to 9 after four weeks, while the mean HAM-D score declined from 28.14 (P = 0.18) to 8.71 (P = 0.09) post-intervention. This preliminary study suggests that the high-power enhanced near-infrared therapy device holds promise in reducing depression among patients suffering from treatment-resistant depression.
Indexed as
Identifiers
41288780What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.